LG-IR-NMIBC Treatment Landscape

Host: Mark L. Gonzalgo, MD, PhD, MBA

Guest: Chad R. Ritch, MD, MBA, FACS

CME Available: auau.auanet.org/node/44036

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

AstraZeneca

Johnson & Johnson

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning.

2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC.

3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.